+

WO2000065088A2 - Amorces servant a l'identification, le typage ou la classification d'acides nucleiques - Google Patents

Amorces servant a l'identification, le typage ou la classification d'acides nucleiques Download PDF

Info

Publication number
WO2000065088A2
WO2000065088A2 PCT/EP2000/003636 EP0003636W WO0065088A2 WO 2000065088 A2 WO2000065088 A2 WO 2000065088A2 EP 0003636 W EP0003636 W EP 0003636W WO 0065088 A2 WO0065088 A2 WO 0065088A2
Authority
WO
WIPO (PCT)
Prior art keywords
primers
primer
extendible
hla
nucleic acid
Prior art date
Application number
PCT/EP2000/003636
Other languages
English (en)
Other versions
WO2000065088A3 (fr
Inventor
Per-Johan Ulfendahl
Kin-Chun Wong
Original Assignee
Amersham Pharmacia Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amersham Pharmacia Biotech Ab filed Critical Amersham Pharmacia Biotech Ab
Priority to AU50625/00A priority Critical patent/AU5062500A/en
Publication of WO2000065088A2 publication Critical patent/WO2000065088A2/fr
Publication of WO2000065088A3 publication Critical patent/WO2000065088A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids

Definitions

  • DNA-sequence analysis is rapidly becoming a standard tool in modern, molecular biology research. Examples of applications include: Sequencing of unknown DNA-sequences, Identifying novel genes in stretches of sequenced DNA, Predicting protein-sequence and -structure from DNA-sequence alone and Identification of known gene-variations (sometimes called "typing a gene").
  • HLA Human Leucocyte Antigen
  • MHC Major Histocompatibility Complex
  • Another application where a rapid and accurate identification of a gene is desired is when trying to identify unknown bacteria.
  • a rapid identification of the bacteria causing the illness of a patient makes it possible to administer the correct medication early in the treatment of the disease, thus reducing the discomfort for the patient.
  • every self- replicating organism so far studied use ribosomes when translating mRNA to proteins, analysis of one of the genes coding for the ribosome, for instance the 16S rRNA in the case of prokaryotes, could be used to identify the organism in question.
  • APEX Arrayed Primer Extension
  • the array primer extension method APEX for resequencing would need more than 16,000 primers if all DQB alleles would be sequenced from a 500 bp long PCR fragment. If all DQB alleles in pairs should be combined the number of primers might be even higher which would be the situation for a heterozygote found in most individuals. But this might not be necessary, if some variations always or never occur together. This needs to be studied though, and a way found to determine the least number of primers (and what their sequences are) required for unambiguously identifying those genes.
  • An object of this invention is to find and implement an efficient algorithm capable of doing just that.
  • the algorithm should preferably also take into account the melting points of the primers, so that the extension reaction can take place under optimal conditions for all of the primers on the chip. It should also minimise the number of "self-extended” primers, i.e. primers that can extend themselves without any sample DNA.
  • This algorithm is then to be tested and evaluated on the HLA and 16S rRNA- genes.
  • HLA is chosen partly because of the importance of rapid typing of these genes, leading to the fact that there are many other methods to which APEX can be compared. It is also because the HLA-genes are "easy” to work with, since they rarely contain any insertions or deletions. These kinds of variations in the gene could potentially create problems when designing primers for APEX.
  • the 16S rRNA contains insertions and deletions and can thus be used to see if the algorithm can handle such variations.
  • the invention provides a method of identifying a set of extendible primers for use in the identification, typing or classification of a nucleic acid of known sequence having known polymorphisms wherein: i) all possible nucleotide sequences of a chosen length of the nucleic acid are identified and their corresponding extendible primers, ii) at least one extendible primer is removed from the set wherein the at least one primer removed identifies a segment of the nucleic acid identified by at least one other primer.
  • the method includes between step i) and ii): ia) potential extensions for each primer are identified with respect to each nucleotide sequence, ib) for each extendible primer the identified potential extensions are compared to determine which pairs of sequences can be discriminated by the primer.
  • a matrix of primers and pairs of primer extensions is prepared in binary form and is subjected to analysis by a set covering problem (SCP) algorithm as described in more detail below.
  • SCP set covering problem
  • the invention also includes a set of extendible primers, for use in the identification, typing or classification of a nucleic acid of known sequence having known polymorphisms, identified by the method as defined.
  • the primers are attached by 5'-ends to a surface of a support on which they are presented in the form of an array.
  • the invention provides a set of extendible primers, for use in the identification, typing or classification of a human leucocyte antigen (HLA) gene as indicated, the set comprising about the number of primers indicated and being capable of distinguishing about the number of alleles indicated:
  • HLA human leucocyte antigen
  • the invention provides a set of extendible primers, for use in the identification, typing or classification of 16S rRNA, wherein the set comprises about 210 primers and is capable of distinguishing at least about 1207 different sequences.
  • the approximate number of primers is indicated. As indicated below, it may be possible by the use of the algorithms exemplified or other algorithms to generate slightly smaller sets of primers capable of distinguishing the number of alleles or sequences indicated, and these sets are envisaged according to the invention. Of course, other primers may be present in addition to those indicated as essential, and may be useful for checking purposes.
  • the number of alleles or sequences indicated represents the approximate known number of polymorphisms or different sequences, and these will surely increase with time.
  • the invention provides a method of identification, typing or classification of a nucleic acid of known sequence having known polymorphisms, by the use of the set of extendible primers as defined, which method comprises applying the nucleic acid or fragments thereof to the set of extendible primers under hybridisation conditions and effecting template-directed chain extension of extendible primers that have formed hybrids.
  • template-directed chain extension is effected using four different fluorescently labelled chain-terminating nucleotide analogues, and results are analysed by an imaging system such as total internal reflection fluorescence (TIRF) or scanning confocal microscopy.
  • TIRF total internal reflection fluorescence
  • the various steps of the method may be performed as described in the literature for the known APEX technique.
  • the invention provides a kit for use in the identification, typing or characterisation of a nucleic acid of known sequence having known polymorphisms, comprising the set of extendible primers as defined.
  • the invention provides an array of sets of extendible primers as defined, for the simultaneous identification, typing or classification of two or more different HLA genes.
  • the present invention it has been realised that where a number of different alleles are to be identified, the total number of primers required to distinguish each of the alleles could be reduced as some primers would be common to all of the alleles, for example.
  • complete sets of primers for identification of each allele are identified and then the total number of primers in the combined sets is reduced using predetermined rules.
  • the present invention is based on the premise that as the primers are used to identify the presence or absence of a particular nucleotide sequence in any allele, the specific nucleotide that extends any particular primer is of less relevance than simply whether the primer has been extended.
  • SCP Set Covering Problem
  • Figure 1 is a diagram of a signal matrix in accordance with the present invention
  • Figure 2 is a diagram of the corresponding binary matrix for the signal matrix of Figure 1 ;
  • Figure 3 is a flow diagram of the steps for reducing the primer set in accordance with the present invention. The following is an explanation to assist in an understanding of the principles underlying the manner in which the number of primers used in the identification of a plurality of sequences may be reduced.
  • the number of primers required to identify k sequences grows as 0(k»l), where / is the length of the sequences as each sequence requires / primers.
  • / is the length of the sequences as each sequence requires / primers.
  • the less the sequences differ from one another the fewer primers are required as many of the primers required for identification of a first sequence may also be of use in identification of another sequence. This effect becomes more pronounced the greater the number of sequences to be identified and the greater the similarities.
  • a signal matrix of k x n can be constructed. Each element in the matrix represents the signal, if any, that is generated by a particular primer with respect to a particular sequence.
  • the signal will either be one of the four nucleotides 'A', 'C ⁇ 'G', or T or no signal '-'.
  • Figure 1 is an example of such a signal matrix where, for example, the signal generated by primer 2 with respect to sequence 3 is T.
  • the signal matrix is then converted into a binary matrix that represents whether the signals for any particular primer differ with respect to different sequences.
  • the same signal 'G' is generated for both sequences 1 and 2 but a different signal T is generated with respect to sequence 3.
  • the binary matrix is constructed by considering each column (each primer) of the signal matrix and comparing each signal in that column in turn.
  • the first row of the matrix represents a comparison of the signals for the first and second sequences
  • the second row represents a comparison of the signals for the first and third sequences
  • the third row represents a comparison of the signals for the second and third sequences.
  • Binary '0' represents the comparison revealing the same signal
  • binary '1 ' represents the comparison reveals different signals.
  • the binary matrix renders the data contained within that matrix suitable for mathematical analysis.
  • SCP Set Covering Problem
  • the most simple heuristic is the greedy algorithm, where columns are added one at a time.
  • the column to be added in each step is chosen so as to cover as many uncovered rows as possible (a row is covered if it has at least one non-zero element).
  • S r is the set of columns already included in the solution at iteration r
  • R r is the set of rows with no non-zero elements at iteration r
  • column; ' / is selected according to:
  • C j / P other terms can be used.
  • Example terms are c,, C j / log 2 Pj or c, / (P j )2.
  • Greedy algorithms of this type are described in "An Efficient Heuristic for Large Set Covering Problems", Vasko, Wilson, Naval Research Logistics Quarterly 1984, 31 :163-171 the contents of which is incorporated herein by reference. The difference is in how much emphasis to place on the cost of the column versus how many rows the column covers. It is shown, however, that this entire class of heuristics share the same worst case behaviour. If we denote the set of columns in the solution as S and the solution value as Z, then the worst case behaviour can be described as:
  • Lagrangian relaxation heuristic is believed to be some kind of Lagrangian relaxation heuristic, where in each iteration the Lagrange multipliers for each column are used to calculate the Lagrangian cost for the columns.
  • Lagrangian relaxation heuristic is described in "A Heuristic Method for the Set Covering Problem", Capara et al Technical Report OR-95-8, Operations Research Group, University of Bologna 1995 the content of which is incorporated herein by reference.
  • a near optimal vector of these costs is then calculated by a subgradient algorithm, before being used as input to a greedy algorithm. This is repeated until no improvements in the solution can be made.
  • Lagrangian subgradient methods the Lagrangian of the original problem is considered instead of the original problem. In this case, the Lagrangian will be
  • u is the Lagrangian multiplier for row / ' .
  • q(u) is the Lagrangian cost associated with column j, and is defined by
  • Equation 5 An optimal solution to Equation 4 is given by
  • L(u) can also be seen as an estimate of the lower bound for the solution, i.e. the sum of the costs for the columns in the optimal solution to the SCP will be > L(u).
  • the solution to the SCP can be found by finding an optimal multiplier vector u instead, but this will require much computation especially for a large SCP. But near-optimal multiplier vectors can be found within short time by using the subgradient vector s(u), defined by
  • u can be refined iteratively by using for example
  • Equation 8 where ⁇ > 0 is a step-size parameter and UB is an upper bound on the value of the solution.
  • the initial u° can be defined arbitrarily.
  • To solve the SCP first a near-optimal multiplier vector u is found. This and Equation 6 is then used as a basis to form a feasible solution. The upper bound UB can then be updated to the value of this feasible solution (if it is better than the previous best solution), and a new near-optimal multiplier vector found and so on until convergence is reached.
  • Another alternative computational method that may be employed to solve such a SCP is 'surrogate relaxation' in which in each iteration a corresponding continuous problem is solved and made feasible before a sub-gradient algorithm is applied.
  • genetic algorithms may be employed in which the 'genome' consists of n bits, one bit for each of the columns.
  • a primer in the selected reduced set may generate a negative, '-', signal rather than a positive signal, A, C, G, T.
  • A, C, G, T a positive signal
  • the least number of positive signals as well as the least number of differences in the signal pattern is preferably larger than one.
  • all possible primers are selected (10) using the standard APEX procedure to produce a first set of primers.
  • a substring of the sequence to be analysed is used to construct one primer, then the substring is displaced by one base and another primer is constructed. This process is carried out from the start of the sequence until the entire sequence has been covered. Both strands of DNA are used and this is repeated for all sequences.
  • the primers should be long enough to be capable of discriminating between exact matches and mismatches involving one or two nucleotide pairs. Conveniently, the primers are 13bp long as this has been found to be sufficient to ensure the reaction, or longer to increase hybrid stability. However, to avoid steric hindrance on the chip each primer may be 5'-tailed. In this example, twelve T's are added to the 5'-end of the primer so that the final length of the primers is 25bp.
  • primers that are not suitable as primers are rejected (12) and the rest is included in a primary primer set.
  • Unsuitable primers are those where the three bases at the 3'-end are complementary to any substring of the primer. In some instances this can result in the primer being extended by a neighbouring primer and not the sample DNA as a template and for that reason such primers are considered unsuitable.
  • any primers that would produce ambiguous signals are identified and rejected (14).
  • a primer produces an ambiguous signal where it is not known which of the four bases is in the relevant position.
  • Each of the remaining primers in the primary set primer is then compared to each sequence in turn to determine whether the primer is extendible by each sequence and if the primer is extendible the base with which it would be extended is determined.
  • a signal matrix of the primers with respect to each of the sequences is thus generated (16).
  • the three bases in the 3'-end of the primer must hybridise to the DNA. Otherwise the enzyme responsible for the extension will not be able to add a nucleotide to the primer. Of the rest of the primer (the poly-T tail excluded), at most two mismatches are allowed, otherwise the primer-DNA duplex is considered to be too unstable to be extended. In ordinary PCR, all the bases must match in order for the primer to be extended. But then the temperature is raised to the melting point, T m , of the primer in the extension step. In APEX, this reaction is carried out at 45°C, which is around 10°-20° below T m of most primers. This means that the primers will hybridise to the DNA despite a few mismatches, which is why two mismatches are allowed here.
  • a primer could hybridise to a sequence in more than one position, and sometimes a primer could hybridise to both strands of one allele and give different signals. In those cases all the different signals are combined to form one resulting signal (e.g. 'A' and 'C together forms 'M', which is the NC-IUB (NC-IUB, 1985) code for this combination).
  • the entries for each row are compared against one another, in other words for each primer the signals produced by the primer for each sequence are compared against each other.
  • a binary matrix is thus generated (18) of the primers with respect to the identity or difference of signals for pairs of sequences.
  • the binary matrix contains non-zero entries where the primer is able to distinguish between a pair of sequences.
  • the number of pairs of sequences that each primer can distinguish between are counted and a score is allocated to each primer (20) in dependence on the total number of pairs of sequences counted. Thus, the number of non-zero elements for each primer are counted.
  • Primers that are unable to distinguish between any pairs of sequences are rejected (22) and the remaining primers are sorted (24) in order of their score with the primers with the higher scores at the beginning.
  • a core of primers is created next (26). The primer with the highest score is selected. Where two primers with equal scores exist, the number of positive signals is determined for each and the primer with the greater number of positive signals is chosen. If both primers remain equal, one is then selected arbitrarily over the other. After the main primer has been selected, the first twenty (five times the desired redundancy which is four here) primers giving positive signals for each sequence in turn are selected for the core. All remaining primers are rejected.
  • a greedy algorithm is then run (28) using the core set of primers to identify the minimum number of primers necessary to distinguish each sequence.
  • primers are added one at a time with each primer being selected in turn in relation to the number of uncovered rows it is capable of covering.
  • the reduced set of primers is checked for any sequences that has fewer than four positive signals and extra primers are added as necessary to meet this minimum requirement.
  • a redundancy check is then performed (30) to identify whether any more primers can be removed. During the redundancy check each primer is "tentatively" removed in turn to see whether the remaining primers meet the minimum requirements.
  • next primer is tried. Otherwise the primer is temporarily removed from the set, and the process continues with the next primer in line. This process continues until no more primers can be removed, in which case the last primer to be removed is added back to the set, and the next primer in line tentatively removed and so on.
  • This can be viewed as a depth-first search of a tree where the nodes are combinations of primers, and the number of primers in each node is one less than in a node one level above. The root node thus contains all primers from the greedy algorithm. It has p (the number of primers after the greedy algorithm) primers in it.
  • CFT a modified algorithm
  • This algorithm consists of three main phases: A subgradient phase where a near-optimal multiplier vector is found, a heuristic phase where a solution to the SCP is found and column-fixing, designed to improve the results of the heuristic phase.
  • a near-optimal multiplier vector u is found using Equation 8. At the beginning, the starting vector u° used is defined as
  • Equation 9 Later calls use the last vector u before column fixing, and apply a small perturbation before using it as the starting vector.
  • the perturbation is randomly (and uniformly) distributed in the range ⁇ 10% for each element.
  • the sequence of multiplier vectors is considered to have converged when the improvement in L(u) in the last 50 iterations is smaller than 0.1 %, or when the number of iterations reached 10 x m.
  • the factor A in Equation 8 was set to 0.1 at the beginning, and was updated as follows: Every 20 iterations, the best and worst lower bounds L(u) during those 20 iterations are compared to each other. If the difference is larger than 1 %, the value of ⁇ is halved.
  • ⁇ is multiplied with 1.5.
  • the upper bound, UB used is the sum of the costs of the first primers that together cover all rows four times. Otherwise it is the value of the best solution found so far.
  • the last vector from the subgradient phase is used to generate a sequence of multiplier vectors (again using Equation 8), and a feasible solution constructed for each of the multiplier vectors.
  • the procedure used to generate a feasible solution is a variation of the greedy algorithm, where each column is scored according to
  • R is the set of uncovered rows in each step.
  • the column with the lowest q i.e. the columns with the best "gain/cost"-ratio, is added in each step to the solution. This continues until no improvements to the best solution (i.e. minimum number of primers) have been made for 50 iterations.
  • the heuristic phase column fixing is applied to the solution. Columns that are absolutely necessary in order for a row to be covered (i.e. if there are only e columns covering a row and each row is to be covered e times) are fixed. These fixed columns are then used as a starting point for the greedy algorithm, and the first max ⁇ [200/mj, 1 ⁇ columns chosen therein are fixed as well.
  • ⁇ max ⁇ c. (w * ), ⁇ + £ ,. M ;
  • u,(K : - 1) is the contribution of row / ' to the gap between the estimated lower and upper bound of the problem. This is then split uniformly between all columns in the solution covering that row. Columns with small ⁇ j (contributing the least to the gap) are then likely to be part of the optimal solution. The p columns with the smallest ⁇ are then fixed before the entire algorithm is applied again to the resulting sub-problem. (Column fixing here has nothing to do with column fixing after the heuristic phase, so columns fixed there need no longer be fixed here), p is the smallest value satisfying
  • the number of columns fixed in this step was also set to be at least one more than in the previous iteration (if no improvements were made). Otherwise the same number of columns would be fixed in a number of iterations before the value of ⁇ is large enough to allow more columns to be fixed.
  • the algorithm is iterated until either the value of the best solution is less than the estimated lower bound, all columns in the best solution found so far are already fixed in the refining step or a time limit is exceeded.
  • the time limit in this case was arbitrarily set to as many seconds as there were rows in the problem. However, the time limit is only checked before the refining step. If it is not exceeded, a whole iteration of the algorithm will be executed before another check is done. Here too a check was done afterwards to see if primers could be removed without breaking any constraints.
  • the primers were initially sorted in order of score, this need not be performed.
  • the algorithms for stripping out redundant primers are capable of operating with any order of primers including a wholly random order. However, slightly better results were obtained when ordering by score was performed.
  • the HLA-sequences were available internally from Amersham Pharmacia Biotech (release December 1997), and included 91 alleles from HLA-A, 202 HLA-B, 47 HLA-C, 11 HLA-DPA1 (coding for the ⁇ -chain), 74 HLA-DPB1 ( ⁇ -chain), 18 HLA-DQA1 , 34 HLA-DQB1 , 192 HLA- DR1 and 35 sequences in all of HLA-DR3, -DR4 and -DR5. The length of these sequences range from ⁇ 250bp to -1100bp.
  • the 16S rRNA-sequences were collected from GenBank
  • Table 1 Details about data sets. The program was written using the Microsoft ® Visual C++ ® , version 5.0 compiler. It was executed on a PC with a Pentium ® MMX 233 MHz processor, 64 MB RAM and Windows ® 95, unless otherwise indicated. All execution times are for the entire program, including I/O.
  • the binary SCP matrices were quite dense. The density (i.e. the number of non-zero elements in the matrix) usually lies around a few percent, of course depending on the application. A higher density means that fewer columns are needed in order to cover all rows. This is offset in this case by the fact that all rows were required to be covered multiple times. Another consequence of this high density is that the number of primers needed according to the greedy algorithm could be much higher than in the optimal solution. (Recall that the worst case behaviour of the greedy algorithm is a function of the largest column-sum of elements.)
  • Table 2 Some details about the binary SCP matrix. Data are calculated for all primers in the primary set.
  • the program could be considered as consisting of two phases.
  • the first phase involves constructing all primers and finding out what kind of signal they will get for each sequence.
  • the second phase is the optimisation phase, were the SCP is solved.
  • Table 3 Number of primers in different stages of the algorithm and time to get signals for all primers.
  • the number of primers in the core are for homozygotes.
  • One explanation to this high density is that the sequences in the data sets are quite similar to each other, so that most primers will hybridise to and give signal for more than one sequence (either the same or different signals).
  • This is also indicated in Table 3, where for some data sets there is a noticeable drop from the number of primers in the first set to the number of primers in the primary set. Most of this reduction is due to a primer having the same signal for all sequences, which in turn means that all sequences have a substring that is similar enough for the primer to hybridise to and that the nucleotide after the primer is the same for all sequences.
  • the 16S rRNA data set has a much lower density, and no reduction in the primers going from the first set of primers to the primary set.
  • sequences in this data set come from organisms which might be only distantly related to each other, there need not be as much similarity between the sequences as there is in the HLA data sets.
  • Table 4 No. of primers after the greedy algorithm and time spent by it. Also final nr. of primers after check for redundancy and the total time spent solving the SCP. *Value from a 300MHz Pentium II with 512MB RAM running Windows NT 4.0. The computation was halted before completion due to time constraints.
  • results from combining HLA sequences in order to differentiate between heterozygous individuals can be found in Table 7.
  • CFT was only used for the two smallest data sets due to the time requirements. It performed slightly better than the greedy algorithm on those, but only by one primer on each data set.
  • Table 7 Results from heterozygous pairs. Number of primers needed, the time spent, how many heterozygotes that did not differ by at least four signals from any other heterozygote and the percentage of total number of heterozygotes. * Value from a 300MHz Pentium II with 512MB
  • Table 8 Heterozygous pairs that do not differ enough in their signal patterns, and how many signals they differ with.
  • Table 9 Number of primers needed to discriminate between heterozygote HLA samples.
  • Primers can be arranged on the surface of a support in such a way that different studied types, genes, alleles, species etc. form easily recognised characters such as figures or letters. These character forming primers can be additional primers of common origin from the gene of interest and be used for validation of the process.
  • DNA Four homozygote for DQB cell lines, with alleles 0402, 0301 , 06011 and 0201.
  • Amplification reagents PCR mix from the Amersham Pharmacia Biotech HLA DQB typing kit, a prototype kit.
  • SAP will degrade (dephosphorylate) all free dNTPs and UDG will remove all dU from the DNA and after heating the strands will be broken at these points. This step is applicable to any DNA fragment.
  • A, C,G, T amino TTT AGC CTT AAC GCC T X TGAC GTCA, where X is A, C. G or T.
  • Cy2 - ddCTP (equal to fluorescein) 50 ⁇ M Cy3 - ddATP 50 ⁇ M
  • the DQB amplification was done according to the method described by Williams et al. -96 using a 33% dUTP mix. After 40 cycles (95°C, 30 sec; 55°C, 30 sec; 72°C, 30 sec), one microliter of the PCR products was tested on a 1.5% agarose gel, before the fragmentation step.
  • the samples were frozen and stored until they were used.
  • the detection system is a total internal reflection fluorescence (TIRF) system, where microscopic slides are placed on top of a prism with oil on to link a laser beam in to the glass slide.
  • the system has light of five different wave lengths from five different lasers to vary between. In this experiment only four were used.
  • TIRF total internal reflection fluorescence
  • the DNA from the four DQB homozygote cell lines were amplified according to the protocol in Williams et al. -96 with two different concentrations of dUTP. In addition to this, DNA from six different heterozygotes were amplified. All amplifications worked well and the expected 300 bp fragment were seen from all samples.
  • Primer chips were washed and fragmented PCR products were incubated on the chip according to the protocol. The image was compared to the expected pattern. The expected pattern was similar to but somewhat different from the recorded pattern, the reason for this is that the set up was planned for a 500 bp fragment, but the actual fragment used was a 300 bp PCR fragment.
  • Figure 4 shows the results from a cell line homozygous for the DQB 0204 allele.
  • the pattern shown in the image is very close or similar to the expected results from exon 2.
  • Another improvement that can be made is the following: As is, the program works only with discrete signals, e.g. either there is a signal 'A' or there is not, either there is a signal 'G' or there is not and so on. A more precise approach would be to predict how strong the signals will be for each primer on each sequence. A rough estimate of the signal strength should be possible given some thermodynamic data about the primers, most notably their melting points. With this information, and knowing the concentration of DNA in the sample among other things, the proportion of primers on the chip that will actually react with the sample DNA should be possible to estimate. It would thus allow a rough estimation of what strength the different signals will have. It will not be very precise, and the estimate might possibly be off by a factor 2 or more, but it will still give some information about what signals to expect from the chip.
  • the temperature at which the reaction on the chip is carried out could be optimised as well. Since the sequences are known, it is possible to estimate the melting point of any primer to any sequence when there are a few mismatches. This could be done for all primers on all sequences, and a range of temperatures calculated. The actual temperature to use could then be chosen so as to be as optimal for as many primers on as many sequences as possible, instead of as now at a standard temperature.
  • the algorithm itself could be improved.
  • the complexity of the redundancy-check phase can be slightly reduced by having a vector consisting of the sums of the rows in each node. For each child-node, the column to be removed is then subtracted from this vector of sums. This operation can be carried out in O(m), and the final complexity will then be 0(m ⁇ N(p, p)) instead.
  • the greedy algorithm another possible improvement is to check the primer set for redundancy each time a primer was added.
  • the complexity for the greedy algorithm will be the same, as the check will take 0(m xp) (i.e. same as each iteration in the greedy algorithm) each time (with the improvement just mentioned). The check could take longer, but that is unlikely as that would imply that one primer could make several other primers redundant.
  • the main advantage is, of course, that no redundancy check with its rather high complexity is needed afterwards.
  • this method is only capable of identifying known gene- variants. If applied to a sample with a previously unknown variant, it is very probable that this new variant will be falsely identified as one of the known variants. It would be very advantageous if this method could be augmented in some way to recognise this fact, and give a warning if there could be an unknown variant in the sample. It could be done by giving a warning when the signal pattern gained differs from the signal pattern from any known variants, but this might not be enough. There is no guarantee that the new variant could not differ in some place not affecting any of the existing primers, which would lead to the new variant being indistinguishable from any of the known variants. Some other way is probably needed as well.
  • TTTGCAAGTCCTCCTC ⁇ T ⁇ TCTCCTCCCGGT ⁇ TCCACAACCCGGTA ⁇ TTGGCCAGGTGGACA ⁇ TTGCGGTTCCTGGAG ⁇ TTCAGCCAGAAGGAC ⁇ TTGACTCGCCTCTGC ⁇ TTTCCAGGACTCGGC
  • TTTTTGTACAGACGC TTCGGTCTCCTTCTT TTGCAATGGGGAGCC TTTGGATCTGGATAA ⁇ ⁇ GATGAAGATGAG
  • GGTCACACCCCG GGGAGTTCCGGGC AGGAGGAGACAAC GGGTGGACACAAC TCTGCTCGGTGAC TGGGGCGGCTTGA GCGCACGTCCTCC TAGGATTTCGTGTA

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne une méthode destiné à identifier un ensemble plutôt petit d'amorces extensibles utilisées dans l'identification, le typage ou la classification d'un acide nucléique d'une séquence connue possédant des polymorphismes connus. Une matrice d'amorces et de paires d'extensions d'amorces est préparée et soumise à une analyse à l'aide d'un algorithme de problème d'ensemble, par exemple un algorithme glouton ou un algorithme heuristique de relaxation lagrangienne. L'invention concerne également des ensembles d'amorces utilisés dans l'identification, la classification ou le typage d'un organisme, d'un allèle ou d'un gène sélectionné dans la classe 1 HLA, la classe 2 HLA et la classe 16S rRNA.
PCT/EP2000/003636 1999-04-26 2000-04-20 Amorces servant a l'identification, le typage ou la classification d'acides nucleiques WO2000065088A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU50625/00A AU5062500A (en) 1999-04-26 2000-04-20 Primers for identifying typing or classifying nucleic acids

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99303215 1999-04-26
EP99303215.0 1999-04-26

Publications (2)

Publication Number Publication Date
WO2000065088A2 true WO2000065088A2 (fr) 2000-11-02
WO2000065088A3 WO2000065088A3 (fr) 2001-08-09

Family

ID=8241346

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/003636 WO2000065088A2 (fr) 1999-04-26 2000-04-20 Amorces servant a l'identification, le typage ou la classification d'acides nucleiques

Country Status (2)

Country Link
AU (1) AU5062500A (fr)
WO (1) WO2000065088A2 (fr)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036679A2 (fr) * 1999-11-15 2001-05-25 Hartwell John G METHODES DE GENERATION DE FRAGMENTS D'ADNc SIMPLE BRIN
WO2001092572A1 (fr) * 2000-06-01 2001-12-06 Nisshinbo Industries, Inc. Ensemble et procede de determination du type de hla
WO2002029659A1 (fr) * 2000-10-04 2002-04-11 International Reagents Corporation Systeme medical utilisant des puces d'adn
WO2003066893A1 (fr) * 2002-02-04 2003-08-14 Vermicon Ag Procede de detection specifique rapide de bacteries pathogenes presentes dans des denrees alimentaires
US6713257B2 (en) 2000-08-25 2004-03-30 Rosetta Inpharmatics Llc Gene discovery using microarrays
WO2004029289A2 (fr) * 2002-09-26 2004-04-08 Roche Diagnostics Gmbh Detection de la susceptibilite de developper des maladies auto-immunes
EP1536021A1 (fr) * 2003-11-27 2005-06-01 Consortium National de Recherche en Genomique (CNRG) Méthode pour le typage de HLA
US7507568B2 (en) 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
US7589212B2 (en) 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7632862B2 (en) 2002-09-25 2009-12-15 Procter & Gamble Company Pharmaceutical compositions that modulate HPTPbeta activity
US7795444B2 (en) 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US7807447B1 (en) 2000-08-25 2010-10-05 Merck Sharp & Dohme Corp. Compositions and methods for exon profiling
EP2371865A2 (fr) 2006-04-07 2011-10-05 Warner Chilcott Company, LLC Anticorps se liant à la protéine tyrosine phosphatase béta humaine (HPTP-ß) et leurs utilisations
US8569348B2 (en) 2009-07-06 2013-10-29 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
EP2722395A1 (fr) 2001-10-15 2014-04-23 Bioarray Solutions Ltd Analyse multiplexée de loci polymorphes par l'interrogation concurrente et la détection au moyen d'enzyme
US8846685B2 (en) 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
AU2012200697B2 (en) * 2001-05-07 2015-02-19 Agriculture Victoria Services Pty Ltd Modification of plant and seed development and plant responses to stresses and stimuli (4)
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
US12043664B2 (en) 2011-10-13 2024-07-23 EyePoint Pharmaceuticals, Inc. Methods for treating vascular leak syndrome and cancer
CN118506875A (zh) * 2024-07-12 2024-08-16 中国科学院心理研究所 Rna病毒引物优选的设计的方法、设备、介质和程序产品

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013396A2 (fr) * 1993-11-11 1995-05-18 U-Gene Research B.V. Procede d'identification de micro-organismes, et dispositifs pour sa mise en oeuvre
WO1995015400A1 (fr) * 1993-12-03 1995-06-08 The Johns Hopkins University Genotypage par analyse simultanee de multiples loci a microsatellites
US5883238A (en) * 1993-03-18 1999-03-16 N.V. Innogenetics S.A. Process for typing HLA-B using specific primers and probes sets
WO1999019509A2 (fr) * 1997-10-10 1999-04-22 Visible Genetics Inc. Procede et trousse d'amplification, de sequençage et de typage de genes hla de classe 1 classiques

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08308596A (ja) * 1995-03-10 1996-11-26 Wakunaga Pharmaceut Co Ltd Ｈｌａの検出

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5883238A (en) * 1993-03-18 1999-03-16 N.V. Innogenetics S.A. Process for typing HLA-B using specific primers and probes sets
WO1995013396A2 (fr) * 1993-11-11 1995-05-18 U-Gene Research B.V. Procede d'identification de micro-organismes, et dispositifs pour sa mise en oeuvre
WO1995015400A1 (fr) * 1993-12-03 1995-06-08 The Johns Hopkins University Genotypage par analyse simultanee de multiples loci a microsatellites
WO1999019509A2 (fr) * 1997-10-10 1999-04-22 Visible Genetics Inc. Procede et trousse d'amplification, de sequençage et de typage de genes hla de classe 1 classiques

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BEIN G ET AL.: "Rapid HLA-DRB1 genotyping by nested PCR amplification" TISSUE ANTIGENS, vol. 39, 1992, pages 68-73, XP000949259 *
BUNCE M ET AL.: "The PCR-SSP manager computer program: A tool for maintaining sequence alignments and automatically updating the specificities of PCR-SSP primers and primer mixes" TISSUE ANTIGENS, vol. 52, 1998, pages 158-174, XP000972134 *
CEREB N ET AL: "LOCUS-SPECIFIC AMPLIFICATION OF HLA CLASS I GENES FROM GENOMIC DNA: LOCUS-SPECIFIC SEQUENCES IN THE FIRST AND THIRD INTRONS OF HLA-A, -B, AND -C ALLELES" TISSUE ANTIGENS,DK,MUNKSGAARD, COPENHAGEN, vol. 45, 1995, pages 1-11, XP000197333 ISSN: 0001-2815 *
DATABASE WPI , 1997 Derwent Publications Ltd., London, GB; AN 059711 XP002133096 "Detection and typing of class I MHC HLA-DR antigens - can check multiple specimens easily and type all HLA-DR (D-related) antigens known to be present in the Japanese population" -& JP 08 308596 A (WAKUNAGA SEIYAKU KK), 26 November 1996 (1996-11-26) *
DOI K AND IMAI H: "Greedy algorithms for finding a small set of primers satisfying cover and length resolution conditions in PCR experiments" GENOME INF. SER., vol. 8, 1997, pages 43-52, XP000900076 *
LEVINE J E ET AL.: "SSOP typing of the tenth international histocompatibility workshop reference cell lines for HLA genes" TISSUE ANTIGENS, vol. 44, 1994, pages 174-183, XP000972173 *
LO V M: "HEURISTIC ALGORITHMS FOR TASK ASSIGNMENT IN DISTRIBUTED SYSTEMS" IEEE TRANSACTIONS ON COMPUTERS,US,IEEE INC. NEW YORK, vol. 37, no. 11, 1 November 1988 (1988-11-01), pages 1384-1397, XP000005083 ISSN: 0018-9340 *
METSPALU A ET AL.: "Arrared primer extension (APEX) for mutation detection using gene specific DNA chips" AMERICAN JOURNAL OF HUMAN GENETICS, vol. 61, no. 4Sup, 1997, page A224 XP000900002 *
OLERUP O ET AL.: "HLA-DQB1 and -DQA1 typing by PCR ampification with sequence-specific primers (PCR-SSP) in 2 hours" TISSUE ANTIGENS, vol. 41, 1993, pages 119-134, XP000972084 *
PIRRUNG M C ET AL.: "Design and use of a solid phase DNA-based computational device to solve satisfiability (SAT) problems" FASEB JOURNAL, vol. 11, no. 9, 1997, page A1214 XP002133095 *
VASKO F J: "An efficient heuristic for large set covering problems" NAVAL RESEARCH LOGISTICS QUARTERLY, vol. 31, 1984, pages 163-171, XP000890158 cited in the application *

Cited By (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036679A2 (fr) * 1999-11-15 2001-05-25 Hartwell John G METHODES DE GENERATION DE FRAGMENTS D'ADNc SIMPLE BRIN
WO2001036679A3 (fr) * 1999-11-15 2001-11-22 John G Hartwell METHODES DE GENERATION DE FRAGMENTS D'ADNc SIMPLE BRIN
WO2001092572A1 (fr) * 2000-06-01 2001-12-06 Nisshinbo Industries, Inc. Ensemble et procede de determination du type de hla
US6713257B2 (en) 2000-08-25 2004-03-30 Rosetta Inpharmatics Llc Gene discovery using microarrays
US7807447B1 (en) 2000-08-25 2010-10-05 Merck Sharp & Dohme Corp. Compositions and methods for exon profiling
WO2002029659A1 (fr) * 2000-10-04 2002-04-11 International Reagents Corporation Systeme medical utilisant des puces d'adn
AU2012200697B2 (en) * 2001-05-07 2015-02-19 Agriculture Victoria Services Pty Ltd Modification of plant and seed development and plant responses to stresses and stimuli (4)
EP2722395A1 (fr) 2001-10-15 2014-04-23 Bioarray Solutions Ltd Analyse multiplexée de loci polymorphes par l'interrogation concurrente et la détection au moyen d'enzyme
WO2003066893A1 (fr) * 2002-02-04 2003-08-14 Vermicon Ag Procede de detection specifique rapide de bacteries pathogenes presentes dans des denrees alimentaires
US7507568B2 (en) 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
US7632862B2 (en) 2002-09-25 2009-12-15 Procter & Gamble Company Pharmaceutical compositions that modulate HPTPbeta activity
US7769575B2 (en) 2002-09-25 2010-08-03 Warner Chilcott, LLC Three dimensional coordinates of HPTPbeta
WO2004029289A2 (fr) * 2002-09-26 2004-04-08 Roche Diagnostics Gmbh Detection de la susceptibilite de developper des maladies auto-immunes
WO2004029289A3 (fr) * 2002-09-26 2004-07-22 Roche Diagnostics Gmbh Detection de la susceptibilite de developper des maladies auto-immunes
EP1536021A1 (fr) * 2003-11-27 2005-06-01 Consortium National de Recherche en Genomique (CNRG) Méthode pour le typage de HLA
US8435740B2 (en) 2003-11-27 2013-05-07 Commissariat A L'energie Atomique Et Aux Energies Alternatives Method for HLA typing
WO2005052189A3 (fr) * 2003-11-27 2005-10-20 Consortium Nat De Rech En Geno Methode de typage hla
US20120157347A1 (en) * 2003-11-27 2012-06-21 Commissariat A L'energie Atomique Method for hla typing
WO2005052189A2 (fr) * 2003-11-27 2005-06-09 Consortium National De Recherche En Genomique (Cnrg) Methode de typage hla
US7820377B2 (en) 2003-11-27 2010-10-26 Commissariat A L'energie Atomique Method for HLA typing
EP2267159A3 (fr) * 2003-11-27 2011-08-10 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Méthode pour le typage de HLA-B
JP2007512014A (ja) * 2003-11-27 2007-05-17 コンソルシャム ナショナル ドゥ ルシェルシュ アン ジェノミック（セーエヌエルジェー） Ｈｌａタイピング方法
JP2011200244A (ja) * 2003-11-27 2011-10-13 Commissariat A L'energie Atomique Et Aux Energies Alternatives Ｈｌａタイピング方法
EP2272986A3 (fr) * 2003-11-27 2011-11-02 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Procédé pour le typage de HLA
US9926367B2 (en) 2006-04-07 2018-03-27 Aerpio Therapeutics, Inc. Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
EP2371865A2 (fr) 2006-04-07 2011-10-05 Warner Chilcott Company, LLC Anticorps se liant à la protéine tyrosine phosphatase béta humaine (HPTP-ß) et leurs utilisations
EP3252079A1 (fr) 2006-04-07 2017-12-06 Aerpio Therapeutics, Inc. Anticorps se liant à la protéine tyrosine phosphatase béta humaine (hptp-ss) et leurs utilisations
US11814425B2 (en) 2006-04-07 2023-11-14 Eye Point Pharmaceuticals, Inc. Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
US8524235B2 (en) 2006-04-07 2013-09-03 Aeripo Therapeutics Inc. Method for treating coronary artery disease using antibody binding human protein tyrosine phosphatase beta(HPTPbeta)
US8106078B2 (en) 2006-06-27 2012-01-31 Warner Chilcott Company, Llc Human protein tyrosine phosphatase inhibitors and methods of use
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US8329916B2 (en) 2006-06-27 2012-12-11 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and method of use
US7589212B2 (en) 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US8258311B2 (en) 2006-06-27 2012-09-04 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US8846685B2 (en) 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US10463650B2 (en) 2006-06-27 2019-11-05 Aerpio Pharmaceuticals, Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US8895563B2 (en) 2006-06-27 2014-11-25 Aerpio Therapeutics, Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US8946232B2 (en) 2006-06-27 2015-02-03 Aerpio Therapeutics, Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US8188125B2 (en) 2006-06-27 2012-05-29 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US8338615B2 (en) 2006-06-27 2012-12-25 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US9126958B2 (en) 2006-06-27 2015-09-08 Aerpio Therapeutics, Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US7795444B2 (en) 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US9795594B2 (en) 2006-06-27 2017-10-24 Aerpio Therapeutics, Inc. Human protein tyrosine phosphatase inhibitors and methods of use
USRE46592E1 (en) 2006-06-27 2017-10-31 Aerpio Therapeutics, Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
US9174950B2 (en) 2009-07-06 2015-11-03 Aerpio Therapeutics, Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
US9949956B2 (en) 2009-07-06 2018-04-24 Aerpio Therapeutics, Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
US8569348B2 (en) 2009-07-06 2013-10-29 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
US12043664B2 (en) 2011-10-13 2024-07-23 EyePoint Pharmaceuticals, Inc. Methods for treating vascular leak syndrome and cancer
CN118506875A (zh) * 2024-07-12 2024-08-16 中国科学院心理研究所 Rna病毒引物优选的设计的方法、设备、介质和程序产品

Also Published As

Publication number Publication date
WO2000065088A3 (fr) 2001-08-09
AU5062500A (en) 2000-11-10

Similar Documents

Publication Publication Date Title
WO2000065088A2 (fr) Amorces servant a l'identification, le typage ou la classification d'acides nucleiques
US6703228B1 (en) Methods and products related to genotyping and DNA analysis
Ellegren Sequencing goes 454 and takes large‐scale genomics into the wild
Hudson Sequencing breakthroughs for genomic ecology and evolutionary biology
Sanchez et al. A multiplex assay with 52 single nucleotide polymorphisms for human identification
Slate et al. Gene mapping in the wild with SNPs: guidelines and future directions
Twyford et al. Next-generation hybridization and introgression
CA2771330C (fr) Procedes et materiaux permettant l'identification de races canines
Kenta et al. Multiplex SNP‐SCALE: a cost‐effective medium‐throughput single nucleotide polymorphism genotyping method
US20100261189A1 (en) System and method for detection of HLA Variants
KR20060103813A (ko) 뉴클레오티드 서열의 실질적인 대표체
EP1056889B1 (fr) Procedes associes a la determination d'un genotype et a l'analyse de l'adn
US20140141436A1 (en) Methods and Compositions for Very High Resolution Genotyping of HLA
Garosi et al. Defining best practice for microarray analyses in nutrigenomic studies
CN108138226B (zh) 单核苷酸多态性和插入缺失的多等位基因基因分型
Lakshmi et al. Mouse genomic representational oligonucleotide microarray analysis: detection of copy number variations in normal and tumor specimens
US20110053789A1 (en) Mircoarray methods
US20040023275A1 (en) Methods for genomic analysis
Lockhart et al. DNA arrays and gene expression analysis in the brain
US6963805B2 (en) Methods for identifying the evolutionarily conserved sequences
Tsukagoshi et al. Isolation and characterization of 17 polymorphic microsatellite loci with tri-and tetra-nucleotide repeat motifs for Ayu (Plecoglossus altivelis) using next-generation sequencing
US20080026367A9 (en) Methods for genomic analysis
US20040126800A1 (en) Regulatory single nucleotide polymorphisms and methods therefor
Tebbutt Genotyping of single nucleotide polymorphisms by arrayed primer extension
KR20250034300A (ko) 재조합 이벤트를 검출하기 위한 방법 및 시스템

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载